ClearPoint Neuro, Inc.

(a) None.

(b) None.

(c)During the quarter ended September 30, 2026, none of our officers or directors adopted orterminated a“Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408 of Regulation S-K, except as follows:

•

On August 18, 2026, Danilo D'Alessandro, our Chief Financial Officer, adopted a new Rule 10b5-1 trading arrangement intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). The trading arrangement expires November 30, 2027, subject to earlier expiration if all transactions thereunder are completed before the scheduled expiration date. A total of 43,269 shares are subject to the plan, plus up to 64,278 additional shares, which are reduced by any shares sold under Mr. D'Alessandro's prior Rule 10b5-1 plan dated November 26, 2025 after August 17, 2026 and before this plan's selling start date. The maximum number of shares to be sold under the plan is therefore 107,547.

•

On September 12,2026, Joseph M. Burnett, our Chief Executive Officer and President, adopted a new Rule 10b5-1 trading arrangement intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). The plan'smaximum duration is until November 5, 2027. The maximum number of shares to be sold under the plan is 250,000.